Pluri's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-5.94 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-26.04 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Pluri's annualizedROC % for the quarter that ended in Mar. 2026 was -57.45%.
Pluri's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -277.21%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Pluri's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -49.95%.
Pluri (NAS:PLUR) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Pluri's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri EBIT Related Terms
Pluri EBIT Historical Data
* Premium members only.
The historical data trend for Pluri's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pluri's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pluri's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (PLUR) has a EBIT of $-26.04 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pluri.
Is Pluri's EBIT too high?
Pluri's current EBIT is $-26.04 Mil. Overall, Pluri has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's EBIT compare to VTGN and PTN?
Pluri's EBIT of $-26.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pluri. Pluri's current EBIT is $-26.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.06 — trading 68.1% below its estimated fair value. The current EBIT is $-26.04 Mil. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pluri (PLUR), the current EBIT is $-26.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (PLUR) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of $2.06 is trading 68.1% below its estimated GF Value™ of $6.46.
GuruFocus considers Pluri to be Possible Value Trap.
Key valuation signals for PLUR:
EBIT: $-26.04 Mil
GF Value™: $6.46 vs. price of $2.06 (68.1% below fair value)
No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for PLUR
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLUR has been successfully added to your 
